Sign In
Buy TRDA
$6.58
-0.0600 (-0.90%)
At Close: Jun 03, 2026
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 02'nd Jun 2025
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units (“RSUs”) to six newly-hir
– Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 –
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
09:20am, Thursday, 08'th May 2025
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to earnings of $0.68 per share a year ago.
Entrada Therapeutics Reports First Quarter 2025 Financial Results
07:00am, Thursday, 08'th May 2025
– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skippi
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for
11:05am, Tuesday, 29'th Apr 2025
Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three n
Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates
09:25am, Thursday, 27'th Feb 2025
Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.66 per share. This compares to loss of $0.29 per share a yea
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
07:00am, Thursday, 27'th Feb 2025
– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
07:00am, Monday, 24'th Feb 2025
– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently r
Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside
11:31am, Wednesday, 19'th Feb 2025
Entrada Therapeutics addresses intracellular drug delivery challenges with its Endosomal Escape Vehicle platform, positioning itself uniquely in the biotech sector. Strong financials with $449.3 milli
– Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing –
Azenta Announces the Election of Dipal Doshi to its Board of Directors
04:05pm, Thursday, 30'th Jan 2025
BURLINGTON, Mass. , Jan. 30, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and a recognized leader i
Best Momentum Stocks to Buy for December 30th
11:01am, Monday, 30'th Dec 2024
CCRD, TRDA and NRXP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2024.
New Strong Buy Stocks for December 30th
07:21am, Monday, 30'th Dec 2024
CCRD, APPN, USNA, TRDA and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2024.
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
07:00am, Wednesday, 18'th Dec 2024
BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class
